Search results for "Rating scale"

showing 10 items of 537 documents

Maintenance of weight loss after obesity treatment: is continuous support necessary?

2002

Abstract Objective: This study examined outcome differences of 109 obese subjects, who participated in a 10-week cognitive-behavioral inpatient treatment followed by either a weight maintenance program or a follow-up period without professional support. Methods: Self-rated weight loss, eating behaviors, and general psychopathology were assessed several months before treatment, when subjects were admitted, at discharge, and at the 6-, 12-, and 18-month follow-ups. Structured interviews for mental disorders and eating pathology were conducted additionally. Results: The mean weight of the sample at baseline was 127 kg. Weight loss of the total sample amounted to 8.0 kg (6.3%) and was completel…

Adultmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentExperimental and Cognitive PsychologySeverity of Illness IndexBody Mass IndexWeight lossSurveys and QuestionnairesWeight maintenanceWeight LossmedicineHumansObesityPsychiatric Status Rating ScalesCognitive Behavioral TherapyMental DisordersProfessional supportmedicine.diseaseObesityPsychiatry and Mental healthClinical PsychologyGeneral psychopathologyStructured interviewPhysical therapyCognitive therapyFemaleObese subjectsmedicine.symptomEnergy IntakePsychologyFollow-Up StudiesBehaviour Research and Therapy
researchProduct

The concept of major depression. III. Concurrent validity of six competing operational definitions for the clinical ICD-9 diagnosis.

1991

The comparative validity of six operational diagnoses of major depression was evaluated in 600 psychiatric inpatients using the independently assessed clinical ICD-9 diagnoses as a yardstick. Agreement with, and positive predictive value for the ICD-9 categories of pure (endogenous and psychogenic) depression served as validation criteria; sensitivity of major depression diagnoses for detecting ICD-9 bipolar depressions was additionally used for examining the adequacy of width, time and exclusion criteria of the competing operational definitions. Three essential results were found. First, the "old" diagnostic definitions of RDC and FDC are superior to all newer definitions because they defi…

Affective Disorders PsychoticBipolar DisorderPsychometricsNeurotic DisordersPsychometricsConcurrent validityMEDLINEValidityDiagnosis DifferentialPsychogenic diseaseHumansPharmacology (medical)Medical diagnosisBiological PsychiatryDepression (differential diagnoses)Psychiatric Status Rating ScalesDepressive DisorderOperational definitionGeneral NeuroscienceGeneral MedicineHospitalizationPsychiatry and Mental healthNeuropsychology and Physiological PsychologySchizophreniaSchizophrenic PsychologyPsychologyClinical psychologyEuropean archives of psychiatry and clinical neuroscience
researchProduct

Risk of drug-related falls among noninstitutionalized older adults

2017

To determine the number of drugs taken per day, which represents a risk factor for falls among noninstitutionalized older adults with a history of falls in the last year.This was a descriptive study that used random sampling and the following measurement instruments: the WHO questionnaire for the study of falls in older adults, gait scale and geriatric depression scale and gait and balance. Univariate and bivariate analysis, nonparametric chi-squared test, and binary logistic regression were performed using the SPSS statistical program version 21.0.214 individuals participated in the study. Those who took ≥ 4 drugs presented higher risk of falling, p=0.010 OR=4.034. The same was not true fo…

Aged 80 and overMalePsychiatric Status Rating ScalesDrug-Related Side Effects and Adverse ReactionsDepressionCross-Sectional StudiesLogistic ModelsPharmaceutical PreparationsRisk FactorsSurveys and QuestionnairesHumansAccidental FallsFemaleGaitGeriatric AssessmentPostural BalanceAged
researchProduct

Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia

1992

Abstract In this randomized double-blind, placebo controlled, multicentre study on 108 elderly patients with mild to moderate mental deterioration of vascular origin, idebenone — a benzoquinone derivative with a hydroxyalkyl side chain — proved to be therapeutically effective in the treatment of multi-infarct dementia. The oral administration of idebenone 45 mg/day b.i.d. for 120 days significantly improved the scores of the following test in comparison with placebo: Mini Mental State, Randt Memory Test, Gottfries Rating Scale, Token Test, Toulouse Pieron Test, indicating improvements in memory attention and cognitivity. The drug was well tolerated and effective in patients with multi-infar…

Agingmedicine.medical_specialtyHealth (social science)Vascular diseaseCerebral infarctionbusiness.industrymedicine.diseasePlaceboClinical trialOral administrationRating scaleAnesthesiamedicinePhysical therapyIdebenoneDementiaGeriatrics and GerontologybusinessGerontologymedicine.drugArchives of Gerontology and Geriatrics
researchProduct

Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms

1994

Twenty schizophrenic inpatients with either predominantly positive or predominantly negative symptoms were treated with the dopamine autoreceptor agonist roxindole in prospective open clinical trials. There was no antipsychotic effect in the subgroup with positive symptoms, whereas the subgroup with negative symptoms, especially those with the residual type of schizophrenia, showed a moderate but significant 20% reduction in total scores on the Scale for the Assessment of Negative Symptoms.

Agonistmedicine.medical_specialtyPsychosismedicine.drug_classDopamine AgentsGastroenterologyReceptors Dopaminechemistry.chemical_compoundRoxindoleInternal medicinemental disordersSchizophrenic PsychologymedicineHumansProspective StudiesScale for the Assessment of Negative SymptomsPsychiatric Status Rating ScalesSchizophrenia ParanoidDose-Response Relationship Drugbusiness.industrymedicine.diseaseHospitalizationPsychiatry and Mental healthTreatment OutcomeEndocrinologychemistrySchizophreniaDopamine receptorSchizophreniaAutoreceptorSchizophrenic PsychologybusinessAmerican Journal of Psychiatry
researchProduct

Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophreniaspectrum disorders: Findings f…

2020

This study, based on the 'Servizi Territoriali Associati per la Ricerca' (STAR) Network Depot Study nationwide baseline data, explored whether individual symptoms severity and clusters might influence the prescription of paliperidone palmitate 1-month (PP1M) vs. aripiprazole monohydrate. The Brief Psychiatric Rating Scale (BPRS) was used to assess psychopathology and relevant symptoms clusters. Drug Attitude Inventory, 10 items, was used to test attitude towards medications. Adherence to treatments was rated according to the Kemp seven-point scale. We assessed for eligibility 451 individuals and, among them, we included 195 subjects (n = 117 who started PPM1 and n = 78 aripiprazole monohydr…

Aripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate; Schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Knowledge Attitudes Practice; Humans; Male; Medication Adherence; Paliperidone Palmitate; Practice Patterns Physicians'; Schizophrenia; Schizophrenic Psychology; Young AdultAdultMaleLong-acting injectable antipsychoticmedicine.medical_specialtyHealth Knowledge Attitudes Practicemedicine.medical_treatmentAripiprazole monohydrate Long-acting injectable antipsychotics Paliperidone palmitate SchizophreniaAripiprazolePractice PatternsLong-acting injectable antipsychoticsMedication Adherence03 medical and health sciencesYoung Adult0302 clinical medicineAripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate; SchizophreniaInternal medicineBrief Psychiatric Rating ScalemedicineHumansPharmacology (medical)Practice Patterns Physicians'AntipsychoticSettore MED/25 - PsichiatriaPaliperidone PalmitatePaliperidone palmitatePracticePhysicians'business.industryHealth KnowledgeAripiprazole monohydratemedicine.disease030227 psychiatryPsychiatry and Mental healthSchizophreniaAttitudesPropensity score matchingSchizophreniaObservational studyAripiprazoleFemaleSchizophrenic Psychologybusiness030217 neurology & neurosurgerymedicine.drugPsychopathologyAntipsychotic Agents
researchProduct

Long-term reliability of the Finnish behavioral and emotional rating scale

2015

In previous research, the Finnish version of the Behavioral and Emotional Rating Scale-2 has demonstrated adequate internal consistency, factor structure and convergent validity. The purpose of the present study was to examine the long-term test-retest reliability of the Finnish BERS-2. Youth, parent and teacher BERS-2 ratings were collected once a year for three years in order to assess the stability of scores. All of the correlations were significant and moderate to very large in magnitude. Study limitations, future research and implications were discussed.

Behavioral and Emotional Rating Scalenuorettunteetmittarit (mittaus)lapset (ikäryhmät)tutkimuspitkittäistutkimusBERS-2käyttäytyminenlong-term test-retest reliabilityluotettavuusmittausmenetelmätSocial welfare : interdisciplinary approach
researchProduct

Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placeb…

2016

Evidence supporting the use of second generation antipsychotics (SGAs) in the treatment of acute depression with mixed features (MFs) associated with bipolar disorder (BD) is scarce and equivocal. Therefore, we conducted a systematic review and preliminary meta-analysis investigating SGAs in the treatment of acute BD depression with MFs. Two authors independently searched major electronic databases from 1990 until September 2015 for randomized (placebo-) controlled trials (RCTs) or open-label clinical trials investigating the efficacy of SGAs in the treatment of acute bipolar depression with MFs. A random-effect meta-analysis calculating the standardized mean difference (SMD) between SGA an…

Bipolar DisorderManic-depressive illness--Treatmentmeta-analysilcsh:ChemistryClinical trials0302 clinical medicineManic-depressive illnessAsenapineAntipsychotic drugslcsh:QH301-705.5Spectroscopydiagnostic and statistical manual for mental disorders fifth edition (DSM-5)PsychiatryDepressionBrief ReportGeneral MedicineComputer Science ApplicationsTreatment OutcomeMeta-analysismixed featureHumanmedicine.drugAntipsychotic Agentsmedicine.medical_specialtyAcute bipolar depression; Diagnostic and statistical manual for mental disorders fifth edition (DSM-5); Meta-analysis; Mixed features; Second generation antipsychotic (SGA); Systematic-review; Physical and Theoretical Chemistry; Organic Chemistry; Spectroscopy; Inorganic Chemistry; Catalysis; Molecular BiologyYoung Mania Rating ScalePlaceboCatalysisInorganic Chemistry03 medical and health sciencessystematic-reviewInternal medicinemedicineHumansZiprasidoneBipolar disorderPhysical and Theoretical ChemistryPsychiatryMolecular BiologyLurasidonemixed featuresbusiness.industryOrganic Chemistrysecond generation antipsychotic (SGA)acute bipolar depressionmedicine.disease030227 psychiatrymeta-analysisAntipsychotic Agentlcsh:Biology (General)lcsh:QD1-999QuetiapineControlled Clinical Trials as Topicbusiness030217 neurology & neurosurgeryInternational Journal of Molecular Sciences
researchProduct

Factor analyses of multidimensional symptoms in a large group of patients with major depressive disorder, bipolar disorder, schizoaffective disorder …

2020

Abstract Background There is an ongoing discussion about which neurobiological correlates or symptoms separate the major psychoses (i.e. Major Depressive Disorder MDD, Bipolar Disorder BD, and Schizophrenia SZ). Psychopathological factor analyses within one of these disorders have resulted in models including one to five factors. Factor analyses across the major psychoses using a comprehensive set of psychopathological scales in the same patients are lacking. It is further unclear, whether hierarchical or unitarian models better summarize phenomena. Method Patients (n = 1182) who met DSM-IV criteria for MDD, BD, SZ or schizoaffective disorder were assessed with the SANS, SAPS, HAMA, HAM-D, …

Bipolar DisorderSchizoaffective disorder03 medical and health sciences0302 clinical medicineHumansMedicineBipolar disorderMedical diagnosisBiological PsychiatryPsychiatric Status Rating ScalesDepressive Disorder Majorbusiness.industrymedicine.diseaseConfirmatory factor analysis030227 psychiatryPsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniaMajor depressive disorderFactor Analysis StatisticalbusinessLarge group030217 neurology & neurosurgeryPsychopathologyClinical psychologySchizophrenia Research
researchProduct

Amyloid precursor protein in platelets: A peripheral marker for the diagnosis of sporadic AD

2001

BACKGROUND: An altered pattern of amyloid precursor protein (APP) forms consisting in a reduced ratio between the upper (130 kDa) and the lower (106 to 110 kDa) immunoreactivity bands has been described in platelets of patients with AD. OBJECTIVE: To evaluate the sensitivity and the specificity of platelet APP forms' ratio (APPr) as a marker for AD. METHODS: Eighty-five patients with probable AD and 95 control subjects (CON), including healthy individuals and neurologic patients, entered the study. Platelet APPr was evaluated by means of Western Blot analysis and immunostaining in the whole platelet homogenate, and calculated by the ratio between the optical density (OD) of the upper (130 k…

Blood PlateletsMalePathologymedicine.medical_specialtyBlood cellCentral nervous system diseaseAmyloid beta-Protein PrecursorDegenerative diseaseWestern blotAlzheimer DiseasemedicineAmyloid precursor proteinHumansPlateletAgedPsychiatric Status Rating Scalesmedicine.diagnostic_testbiologybusiness.industryMiddle Agedmedicine.diseaseAbnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer diseasemedicine.anatomical_structureAmyloid precursor proteinbiology.proteinFemaleSettore MED/26 - NeurologiaNeurology (clinical)Alzheimer's diseasebusinessImmunostainingBiomarkers
researchProduct